Bacterial Therapy
Bacterial Therapy - Related Videos
02:52
Blue Light Therapy for Drug-Resistant Bacterial Infections in Burn Wounds in a Mouse Model
0 Views •
2026
Source: Wang, Y., et al. In Vivo Investigation of Antimicrobial Blue Light Therapy for Multidrug-resistant Acinetobacter baumannii Burn Infections Using Bioluminescence Imaging. J. Vis. Exp. (2017)This video demonstrates the procedure for treating burn wound infections caused by bioluminescent, drug-resistant bacteria in mice using blue light therapy, followed by bioluminescence imaging to monitor treatment efficacy.
11:00
3D Flipwell Engineering for Developing Asynchronous Systems for Toxicologic and Immunomodulatory Therapies in Bacterial, Gut, and Immune Cells
0 Views •
2025
This article provides a detailed protocol with key steps to guide the 3D Flipwell engineering and utilization. We describe and show how to assemble the co-culture insert stacks and utilize them for co-culturing stratified layers of gut bacteria, gut epithelia, and macrophages to model the gut mucosal environment.
05:06
Bioluminescent Bacterial Imaging In Vivo
0 Views •
Cited by 9 •
2012
This article describes the administration of lux-tagged bacteria to mice and subsequent in vivo analysis using IVIS bioluminescence imaging.
05:21
Bacterial Transformation - Student Protocol
0 Views •
2019
Bacterial Transformation ExpandIMPORTANT: In addition to wearing the appropriate personal protective equipment, be sure to take care to keep your face away from suspension cultures, and to avoid inhaling reagents. Do not touch your face while performing the experiment. Always wash your hands before and after every experiment. When you are ready to safely begin, check to make sure you have a tube or tubes of competent E. coli cells in your ice bucket. Then, transfer 50 µL from one of these tubes...
03:57
Bacterial Infection Quantitation Assay: A Method to Quantify Intraocular Bacterial Load in Mouse Model of Bacterial Endophthalmitis
0 Views •
2025
This video describes the technique of quantifying bacterial infection from eye homogenates obtained from a murine model of bacterial endophthalmitis caused by Bacillus cereus. This technique helps study the host immune response and its dependency on the host and ocular bacterial gene expression in murine models.
FAQs
Beneficial bacteria can suppress pathogens by competing for nutrients and attachment sites, while some strains produce antimicrobial compounds that directly affect nearby microbes. These mechanisms act within local microbial communities rather than relying only on system-wide drug exposure. Their relative contribution helps researchers interpret whether treatment success reflects ecological competition, antimicrobial activity, or both.
Engineered strains add a delivery function to the treatment strategy. They can be designed to release therapeutic molecules at specific sites, connecting bacterial localization with a desired biological effect. This approach is relevant when researchers want the introduced organism to do more than occupy a niche or alter microbial metabolism, although safety and host interaction remain important considerations.
Changes in local metabolites provide another route to therapeutic activity. Introduced bacteria may alter the chemical environment around microbial communities, which can influence pathogen behavior or host responses. At the same time, bacterial stimulation of immune responses makes immunology central to evaluating outcomes: researchers must distinguish effects associated with microbial competition from those associated with host immune activation.
Safety, persistence, host interactions, and treatment efficacy are interdependent evaluation criteria. A strain that remains present may have greater opportunity to act, but persistence also makes its host relationship important to characterize. Assessing these features together helps determine whether an observed benefit supports responsible development and whether the intervention behaves predictably in its intended setting.
Bacterial therapy is being investigated as an alternative to conventional antibiotics, particularly when researchers seek effects based on microbial ecology, local metabolites, immune stimulation, or targeted delivery. The comparison is not simply about replacing one treatment with another: development must establish whether the bacterial approach provides efficacy while meeting safety and persistence requirements.
Research applications extend beyond infectious disease. Microbiome-based treatments and live biotherapeutic products are being explored in relation to inflammatory disorders, while engineered bacterial strategies also support cancer-therapy research. These applications share a need to connect the bacterial intervention with its site of action, host interactions, and measurable therapeutic efficacy.